Overview

Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN)

Status:
Withdrawn
Trial end date:
2011-06-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this program is to determine the frequency of the use of Posaconazole in immunocompromised patients refractory to first line therapy receiving therapeutic treatment based on different pathogens in comparison to other antifungal therapy. A further objective is to determine the frequency of the use of Posaconazole in immunocompromised patients receiving prophylactic treatment in comparison to other antifungal prophylaxis.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Posaconazole
Criteria
Inclusion Criteria:

- Immunocompromised patients with refractory IFI

- Patients eligible for prophylactic treatment due to anticipated neutropenia for more
than 7 days.

Exclusion Criteria:

- None